Published in final edited form as:

J Am Chem Soc. 2015 March 11; 137(9): 3229–3232. doi:10.1021/jacs.5b00620.

An Immunosuppressive Antibody-Drug Conjugate

Rongsheng E. Wang^{†,||}, Tao Liu^{†,||}, Ying Wang[‡], Yu Cao[†], Jintang Du[‡], Xiaozhou Luo[†], Vishal Deshmukh[†], Chan Hyuk Kim[‡], Brian R. Lawson^{‡,§}, Matthew S. Tremblay[‡], Travis S. Young[‡], Stephanie A. Kazane^{‡,*}, Feng Wang^{‡,*}, and Peter G. Schultz^{†,‡,*}

[†]Department of Chemistry and the Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, California 92037, United States

[‡]California Institute for Biomedical Research (Calibr), La Jolla, California 92037, United States

[§]Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California 92037, United States

Abstract

We have developed a novel antibody drug-conjugate (ADC) which can selectively deliver the Lck inhibitor dasatinib to human T lymphocytes. This ADC is based on a humanized antibody which selectively binds with high affinity to CXCR4, an antigen that is selectively expressed on hematopoietic cells. The resulting dasatinib-antibody conjugate suppresses T-cell-receptor (TCR)-mediated T cell activation and cytokine expression with low nM EC₅₀ and has minimal effects on cell viability. This ADC may lead to a new class of selective immunosuppressive drugs with improved safety, and extends the antibody-drug conjugate strategy to the targeted delivery of kinase inhibitors for indications beyond oncology.

Antibody-drug conjugates (ADCs) are an emerging class of immunotherapeutic agents that allow the targeted delivery of potent cytotoxic agents to cancer cells.¹ A number of toxins such as doxorubicin, auristatin, and calicheamicin have been conjugated to monoclonal antibodies that selectively bind various antigens overexpressed in cancers.^{2–4} Examples include trastuzumab-DM1 and brentuximab-vedotin which were recently FDA approved for the treatment of HER2-overexpressing breast cancer and Hodgkin's lymphoma, respectively.¹ Despite substantial progress in the development of ADCs in oncology, few applications using non-cytotoxic agents outside the field of oncology have been reported.⁵ To this end, we asked whether an ADC approach can be applied to other classes of small molecule drugs, in particular kinase inhibitors, for the treatment of autoimmune and inflammatory diseases.^{6,7} Unfortunately, many kinase inhibitors, including those currently in clinical use, suffer from a lack of selectivity for related kinase family members, leading to off-target toxicity. This low therapeutic index has largely limited kinase inhibitors to the

Corresponding Authors: spinkerton@calibr.org, fwang@calibr.org, schultz@scripps.edu.

Author Contributions

These authors contributed equally

The authors declare no competing financial interests

Supporting Information

Experimental details and supporting figures. This material is available free of charge via the Internet at <http://pubs.acs.org>

treatment of cancer, despite their considerable potential in other disease settings.^{8,9} For example, dasatinib, which is used clinically for the treatment of BCR-ABL-dependent chronic myelogenous leukemia, is also a potent inhibitor ($IC_{50} < 1$ nM) of other Src-family kinases. These include Lck and Fyn,^{10,11} which play key roles in T cell receptor (TCR) signaling by phosphorylating and activating downstream kinases, including ZAP70.^{12,13} Despite its promise for the treatment of T-cell mediated immune disorders, the lack of selectivity of dasatinib leads to severe side effects including nausea, neutropenia, and pleural effusions,^{14,15} that undermine its development as an immunosuppressive agent. Given its lack of selectivity, but highly potent activity in inhibiting T cell activation, we asked whether we could selectively target dasatinib to T cells as an antibody-drug conjugate and thereby improve its therapeutic index.

To selectively deliver dasatinib to T lymphocytes, we considered a number of antibodies that selectively bind T cell antigens, including CD3, CD4, CD70, and CD184 (CXCR4). Among these, CXCR4 is highly expressed on the surface of human T cells (Figure S1),^{16,17} but has minimal to no expression on non-hematopoietic cells as well as resting neutrophils.^{17–19} Although CXCR4 is also expressed on hematopoietic stem cells (HSCs), B-cells, and monocytes, delivery of dasatinib to these cells is not likely to cause serious side effects.^{16,17,20,21} Moreover, it has been demonstrated that antibodies that bind CXCR4 are efficiently internalized, and their antagonism of CXCR4-signalling is not associated with significant adverse clinical effects,^{22–25} suggesting they are excellent candidates for conjugation with dasatinib.

We recently developed an anti-CXCR4 antibody that specifically binds to CXCR4 with high affinity by grafting a CXCR4 peptide antagonist into the extended complementarity determining region (CDR) of the bovine antibody (BLV1H12) scaffold.²⁶ However, to use this antibody in an ADC, we needed to first generate a humanized version in order to avoid a neutralizing immune response upon chronic administration. To this end, we grafted the long CDR3H of the bovine anti-CXCR4 antibody²⁶ into CDR3H of trastuzumab, an antibody with minimal immunogenicity in humans (Figure 1A). The long CDR3H of the bovine anti-CXCR4 consists of a disulfide cross-linked β -hairpin peptide that specifically binds the ligand binding pocket of CXCR4. The CXCR4 targeting hairpin peptide was inserted into CDR3H between Arg98 and Asp108, replacing the original Trp99–Met107 loop in CDR3H of trastuzumab, to afford the humanized antibody HLCX (Figure 1A, 1B). HLCX was transiently expressed in HEK 293F cells and purified by Protein G chromatography with a final yield of ~5 mg/L. Denaturing SDS/PAGE gel electrophoresis demonstrated that the antibody was > 90% pure and resolved into bands of ~150 kDa (non-reducing conditions, full length IgG) and ~50 and ~25 kDa (reducing conditions, heavy and light chains, respectively) (Figure S2A). Further analysis of HLCX by electrospray-ionization mass spectrometry (ESI-MS) indicated the expected molecular weight (Figure S2B).

We next examined the binding of HLCX to cell-surface CXCR4 by flow cytometry. Incubation of 10 nM HLCX with Jurkat T cells (CXCR4^{high})²⁵ resulted in a peak shift of 96.2% by flow cytometry analysis (Figure 1C). In contrast incubation of HLCX with MDA-MB435 cells (CXCR4^{neg})²⁷ did not result in any shift (Figure 1D), indicating that HLCX binds human CXCR4 selectively. Given that HLCX was derived from the trastuzumab

scaffold, we also tested the binding of HLCX to HER2-transfected MDA-MB435 cells²⁸ (Figure S3). A minimal peak shift (Figure 1E) demonstrated that fusion into the CDR3H of trastuzumab abrogates binding to its cognate antigen.²⁹ To further characterize the binding profile of HLCX, a series of flow cytometry analyses were performed on additional cell lines expressing different levels of CXCR4 (Figure S4), which further confirmed that HLCX is a selective antibody towards CXCR4. We then directly measured the binding affinity of HLCX to human CXCR4 using Tag-lite homogeneous time-resolved fluorescence (HTRF) as described previously.^{26,30} The K_d value for HLCX was determined to be 2.1 ± 0.2 nM (Figure 1F).

Given its selectivity and high affinity, we next examined the internalization of HLCX by human T-cells, as this is required for efficient delivery of the drug to its intracellular target by an ADC. The antibody was conjugated with Alexa Fluor 488 (AF488) by reacting lysyl amino groups with AF488-NHS ester to achieve a drug-to-antibody ratio (DAR) of ~ 4 (Figure S5). Confocal microscopic analysis was used to determine the efficiency of endocytosis of the antibody into human T cells (Figure 2). For comparison, a common anti-CXCR4 commercial clone (12G5) was also conjugated to AF488 at a similar DAR (Figure S6). As shown in Figure 2A, HLCX-AF488 (green spots) was observed in the cytoplasm of T cells within 30 min at 37 °C, indicating efficient endocytosis. Internalization was inhibited at 4 °C (Figure 2B) or in the presence of 20-fold excess of unconjugated HLCX (Figure 2D), indicating that endocytosis is CXCR4-mediated. In contrast, a lower amount of 12G5-AF488 was observed inside the cytoplasm, suggesting that 12G5 is internalized less efficiently than HLCX (Figure 2C). It is known that internalization efficiency depends on binding epitopes.³¹ The long CDR3H of HLCX targets the ligand binding pocket of CXCR4,²⁶ which may contribute to its high internalization efficiency. Taken together, these results suggest that HLCX is an excellent candidate for CXCR4-targeted delivery.

Next, we designed and synthesized dasatinib-linker derivatives for conjugation with HLCX (Scheme 1). Structure-activity relationship and modeling studies have indicated that the hydroxyl moiety of dasatinib is not essential for activity.^{12,13} Therefore we installed a linker for conjugation to the antibody by modifying the hydroxyl group of dasatinib with p-nitrophenyl chloroformate, followed by carbamylation with a tetra-polyethylene glycol (PEG) linker bearing a protected aminoxy moiety for conjugation (Scheme S1). The resulting intermediate was readily deprotected to afford the desired derivative **1** with a non-cleavable linker (Scheme 1). An *in vitro* kinase inhibition assay with Lck (Figure S9) confirmed that this derivative had a similar potency as the parent compound ($EC_{50} = 65.2 \pm 5.1$ pM for **1** vs. 21.6 ± 1.9 pM for dasatinib). Since it has been reported that cleavable linkers may enhance the efficacy of antibody drug conjugates,^{32–34} we also prepared a dasatinib disulfide-cleavable linker **2**, which consists of a peptide spacer unit to increase solubility,^{32,34} an alkoxy-amine group for conjugation, and a disulfide bond to be selectively cleaved inside cells to release the amino-substituted dasatinib derivative (which has a two-fold higher K_d relative to dasatinib (Figure S10)) (Scheme S2).³⁵

Next we developed a versatile two-step coupling procedure for the synthesis of the ADC (Scheme 1). The first step involved nonspecific derivatization of the lysyl amino groups of the antibody with S-4FB linker (Solulink), followed by desalting chromatography to

introduce aryl aldehydes in a stoichiometry of ~ 3 aldehydes : 1 antibody. The modified antibody was then reacted with a 30-fold excess of aminoxy-derived dasatinib linker compounds at 37 °C, for 24 hours in >95% yield as determined by ESI-MS. The resulting antibody conjugates with the non-cleavable linker and disulfide-cleavable linkers, designated as HLCX-dasatinib and HLCX-SS-dasatinib, respectively, were then purified by size exclusion chromatography (Superdex-200). SDS-PAGE (Figure S7) and ESI-MS (Figure S8) showed that the dasatinib ADCs were > 90% pure with a DAR of ~3 and have the expected molecular weights.

To evaluate their *in vitro* activity, the two ADCs were incubated with freshly isolated human T cells that were stimulated with anti-CD3/anti-CD28 antibodies.¹¹ T cells express CD69 surface antigen during early stage activation and gradually express an increasing amount of CD25 as stimulation continues.³⁶ Simultaneously, cytokines such as IL-2, TNF α , and IFN γ are secreted by T cells to promote their proliferation as well as help activate other accessory cells.¹¹ Analysis by flow cytometry (Figure S11) and ELISA (Figure 3A) showed that both ADCs inhibited CD69/CD25 expression and suppressed cytokine secretion at concentrations as low as 8 nM, while the unconjugated HLCX antibody displayed minimal effects (EC_{50} > 200 nM), (Figure 3, Figure S11, and Figure S12). HLCX-SS-dasatinib was ~2-fold more potent than HLCX-dasatinib in suppressing IL-2 (EC_{50} = 12.7 ± 5.8 nM vs. 32.1 ± 11.3 nM), TNF α (EC_{50} = 26.3 ± 9.0 nM vs. 66.1 ± 30.5 nM), and IFN γ (EC_{50} = 58.7 ± 28.6 nM vs. 123.5 ± 43.3 nM). This relatively small difference in activity could be due to differences in the efficiencies of internalization and/or drug release, differences in the potencies of the dasatinib analogues, or differences in drug residence times in the cell. However, to ensure that the increased potency of HLCX-SS-dasatinib is not due to premature release of dasatinib outside the cells, we conjugated the disulfide cleavable dasatinib to a control antibody, trastuzumab, in a similar manner as above, and evaluated its activity in cytokine secretion assays. Trastuzumab-SS-dasatinib showed negligible effects at concentrations up to 200 nM, whereas dasatinib itself completely suppressed cytokine secretion (EC_{50} s ~ 0.2 nM – 1.6 nM) (Figure S13). Additionally, to rule out the possibility that the observed immunosuppression is due to an unexpected cytotoxic activity, the viability of T cells was also measured using CellTiter Glo (Figure S12B). As compared to untreated T cells, the activated T cells did not show any significant loss in viability after incubation with either dasatinib or ADCs at concentrations up to 200 nM.

Although suppression of T cell activation by the dasatinib-ADCs is CXCR4-dependent, we wanted to confirm that the underlying activity is due to inhibition of Lck by dasatinib. To this end, western blot analysis was carried out to examine the phosphorylation of downstream kinases during TCR-induced T cell activation (Figure 3B). As shown in lane 1, TCR activation occurs after crosslinking T cells with OKT3 at 37 °C. Dasatinib, as a positive control, efficiently blocked Lck-mediated phosphorylation of tyrosine on multiple kinases including ZAP70 (lane 2). As indicated in lane 4, HLCX-SS-dasatinib (100 nM) also blocked Lck signaling, whereas HLCX itself (lane 3) and trastuzumab-SS-dasatinib (negative control) displayed negligible effects (lane 5). Taken together, suppression of T cell activation by HLCX-SS-dasatinib ADC is both antibody and small-molecule dependent,

suggesting that a relatively promiscuous kinase inhibitor can be successfully delivered to T cells by the anti-CXCR4 antibody HLCX.

In conclusion, we have developed a novel ADC using a humanized CXCR4-specific IgG with an elongated CDR3 that was nonspecifically conjugated to dasatinib derivatives via both cleavable and non-cleavable linkers. These ADCs are able to selectively deliver dasatinib to human T cells with excellent *in vitro* immunosuppressive activity, which is likely in part due to the high potency of the parent kinase inhibitor. The *in vivo* efficacy of the CXCR4-dasatinib conjugate was not evaluated in rodents due to significant differences in CXCR4 expression in rodent vs human T-cells.³⁷ Further evaluation of the conjugates in a more advanced surrogate model (e.g., cynomolgus monkeys) will be required to determine its therapeutic potential as a tissue-targeted immunosuppressive drug with the potential for improved efficacy and safety. In addition, we are comparing the activity of these ADCs with ADCs site-specifically modified with dasatinib.²⁸ Finally, this work suggests that the ADC strategy has applicability beyond the field of oncology as a route to improve the selectivity of highly potent biologically active small molecules including kinase inhibitors.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Dr. Aaron Pearson (TSRI) for help on solid phase synthesis, and Dr. Damien Bresson (Ambrx, Inc.) for helpful discussions. This work was supported by funding from The California Institute for Biomedical Research to the Scripps Research Institute.

References

1. Sassoon I, Blanc V. *Methods Mol Biol.* 2013; 1045:1. [PubMed: 23913138]
2. Sutherland MS, Sanderson RJ, Gordon KA, Andreyka J, Cervený CG, Yu C, Lewis TS, Meyer DL, Zabinski RF, Doronina SO, Senter PD, Law CL, Wahl AF. *J Biol Chem.* 2006; 281:10540. [PubMed: 16484228]
3. Dubowchik GM, Firestone RA, Padilla L, Willner D, Hofstead SJ, Mosure K, Knipe JO, Lasch SJ, Trail PA. *Bioconjug Chem.* 2002; 13:855. [PubMed: 12121142]
4. Ricart AD. *Clin Cancer Res.* 2011; 17:6417. [PubMed: 22003069]
5. Graversen JH, Svendsen P, Dagnaes-Hansen F, Dal J, Anton G, Etzerodt A, Petersen MD, Christensen PA, Møller HJ, Møestrup SK. *Mol Ther.* 2012; 20:1550. [PubMed: 22643864]
6. Bhagwat SS. *Purinergic Signal.* 2009; 5:107. [PubMed: 18568424]
7. Patterson H, Nibbs R, McInnes I, Siebert S. *Clin Exp Immunol.* 2014; 176:1. [PubMed: 24313320]
8. *Drugs R D.* 2010; 10:271. [PubMed: 21171673]
9. McCormack PL. *Drugs.* 2014
10. Blake S, Hughes TP, Mayrhofer G, Lyons AB. *Clin Immunol.* 2008; 127:330. [PubMed: 18395492]
11. Schade AE, Schieven GL, Townsend R, Jankowska AM, Susulic V, Zhang R, Szpurka H, Maciejewski JP. *Blood.* 2008; 111:1366. [PubMed: 17962511]
12. Das J, Chen P, Norris D, Padmanabha R, Lin J, Moquin RV, Shen Z, Cook LS, Doweiko AM, Pitt S, Pang S, Shen DR, Fang Q, de Fex HF, McIntyre KW, Shuster DJ, Gillooly KM, Behnia K, Schieven GL, Wityak J, Barrish JC. *J Med Chem.* 2006; 49:6819. [PubMed: 17154512]

13. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LA, Das J, Doweyko AM, Fairchild C, Hunt JT, Inigo I, Johnston K, Kamath A, Kan D, Klei H, Marathe P, Pang S, Peterson R, Pitt S, Schieven GL, Schmidt RJ, Tokarski J, Wen ML, Wityak J, Borzilleri RM. *J Med Chem.* 2004; 47:6658. [PubMed: 15615512]
14. Brooks HD, Glisson BS, Bekele BN, Johnson FM, Ginsberg LE, El-Naggar A, Culotta KS, Takebe N, Wright J, Tran HT, Papadimitrakopoulou VA. *Cancer.* 2011; 117:2112. [PubMed: 21523723]
15. Ramchandren R, Schiffer CA. *Biologics.* 2009; 3:205. [PubMed: 19707409]
16. Bleul CC, Wu L, Hoxie JA, Springer TA, Mackay CR. *Proc Natl Acad Sci U S A.* 1997; 94:1925. [PubMed: 9050881]
17. Hori T, Sakaida H, Sato A, Nakajima T, Shida H, Yoshie O, Uchiyama T. *J Immunol.* 1998; 160:180. [PubMed: 9551970]
18. Nagase H, Miyamasu M, Yamaguchi M, Imanishi M, Tsuno NH, Matsushima K, Yamamoto K, Morita Y, Hirai K. *J Leukoc Biol.* 2002; 71:711. [PubMed: 11927659]
19. Weisel KC, Bautz F, Seitz G, Yildirim S, Kanz L, Mohle R. *Mediators Inflamm.* 2009; 2009:790174. [PubMed: 19390584]
20. Lee B, Sharron M, Montaner LJ, Weissman D, Doms RW. *Proc Natl Acad Sci U S A.* 1999; 96:5215. [PubMed: 10220446]
21. Bleul CC, Schultze JL, Springer TA. *J Exp Med.* 1998; 187:753. [PubMed: 9480985]
22. Signoret N, Oldridge J, Pelchen-Matthews A, Klasse PJ, Tran T, Brass LF, Rosenkilde MM, Schwartz TW, Holmes W, Dallas W, Luther MA, Wells TN, Hoxie JA, Marsh M. *J Cell Biol.* 1997; 139:651. [PubMed: 9348282]
23. Kumar A, Humphreys TD, Kremer KN, Bramati PS, Bradfield L, Edgar CE, Hedin KE. *Immunity.* 2006; 25:213. [PubMed: 16919488]
24. Kohler RE, Comerford I, Townley S, Haylock-Jacobs S, Clark-Lewis I, McColl SR. *Brain Pathol.* 2008; 18:504. [PubMed: 18422759]
25. Hesselgesser J, Liang M, Hoxie J, Greenberg M, Brass LF, Orsini MJ, Taub D, Horuk R. *J Immunol.* 1998; 160:877. [PubMed: 9551924]
26. Liu T, Liu Y, Wang Y, Hull M, Schultz PG, Wang F. *J Am Chem Soc.* 2014; 136:10557. [PubMed: 25041362]
27. Liang Z, Wu T, Lou H, Yu X, Taichman RS, Lau SK, Nie S, Umbreit J, Shim H. *Cancer Res.* 2004; 64:4302. [PubMed: 15205345]
28. Axup JY, Bajjuri KM, Ritland M, Hutchins BM, Kim CH, Kazane SA, Halder R, Forsyth JS, Santidrian AF, Stafin K, Lu Y, Tran H, Seller AJ, Biroc SL, Szydluk A, Pinkstaff JK, Tian F, Sinha SC, Felding-Habermann B, Smider VV, Schultz PG. *Proc Natl Acad Sci U S A.* 2012; 109:16101. [PubMed: 22988081]
29. Zhang Y, Liu Y, Wang Y, Schultz PG, Wang F. *J Am Chem Soc.* 2014
30. Lazareno S, Birdsall NJ. *Br J Pharmacol.* 1993; 109:1110. [PubMed: 8401922]
31. Terp MG, Olesen KA, Arnsperg EC, Lund RR, Lagerholm BC, Ditzel HJ, Leth-Larsen R. *J Immunol.* 2013; 191:4165. [PubMed: 24043904]
32. Leamon CP, Reddy JA, Vlahov IR, Kleindl PJ, Vetzal M, Westrick E. *Bioconjug Chem.* 2006; 17:1226. [PubMed: 16984132]
33. Polson AG, Calemene-Fenaux J, Chan P, Chang W, Christensen E, Clark S, de Sauvage FJ, Eaton D, Elkins K, Elliott JM, Frantz G, Fuji RN, Gray A, Harden K, Ingle GS, Kljavin NM, Koeppen H, Nelson C, Prabhu S, Raab H, Ross S, Slaga DS, Stephan JP, Scales SJ, Spencer SD, Vandlen R, Wranik B, Yu SF, Zheng B, Ebens A. *Cancer Res.* 2009; 69:2358. [PubMed: 19258515]
34. Vlahov IR, Leamon CP. *Bioconjug Chem.* 2012; 23:1357. [PubMed: 22667324]
35. Fischer JJ, Dalhoff C, Schrey AK, Graebner OY, Michaelis S, Andrich K, Glinski M, Kroll F, Sefkow M, Dreger M, Koester H. *J Proteomics.* 2011; 75:160. [PubMed: 21664307]
36. Arva E, Andersson B. *Scand J Immunol.* 1999; 49:237. [PubMed: 10102640]
37. Schabath R, Muller G, Schubel A, Kremmer E, Lipp M, Forster R. *J Leukoc Biol.* 1999; 66:996. [PubMed: 10614783]

Figure 1.

(A) Crystal structure of trastuzumab Fab (PDB code: 1N8Z). CDR3H of trastuzumab is labeled in red, and the side chains of Arg98 and Asp108 are marked. (B) A graphic representation of anti-CXCR4 antibody (HLCX) design. A disulfide cross-linked CXCR4-specific β-hairpin peptide (red) stabilized by an anti-parallel β-stranded linker (blue) was engineered onto the CDR3H loop of trastuzumab. (C)–(E) Flow cytometry histogram showing the binding of HLCX to CXCR4-expressing Jurkat T cells (C), CXCR4-negative MDA-MB435 cells (D), and HER2-transfected MDA-MB435 cells (E). (F) Measurement of binding affinity between HLCX and human CXCR4 by a Tag-lite HTRF binding assay.

Figure 2.

Confocal microscopy of internalization of anti-CXCR4 antibodies labeled with Alexa Fluor 488. Human T cells were incubated with 50 nM HLCX-AF488 for 30 min at 37 °C (A), or 4 °C (B), or 50 nM 12G5-AF488 at 37 °C (C), or 50 nM HLCX-AF488 at 37 °C in the presence of 1 μM HLCX (D). Cells were then fixed, stained with Hoechst dye (blue, nucleus), Alexa Fluor 594-conjugated wheat germ agglutinin (red, membrane), and imaged with a Leica 710 confocal microscope. Bar = 2 μm.

Figure 3.

Inhibition of TCR-mediated activation of human T cells. (A) Inhibition of cytokine secretion (Interleukin-2 and TNFα) of αCD3/αCD28-activated T cells by dasatinib (positive control, EC₅₀s ~ 0.2 nM – 1 nM), unconjugated HLCX (negative control), HLCX-dasatinib non-cleavable ADC (EC₅₀ for IL-2: 32.1 ± 11.3 nM; EC₅₀ for TNFα: 66.1 ± 30.5 nM) and HLCX-SS-dasatinib cleavable ADC (EC₅₀ for IL-2: 12.7 ± 5.8 nM; EC₅₀ for TNFα: 26.3 ± 9.0 nM). (B) Western blot for TCR complex signal transduction. T cells were stimulated without compound treatment (lane 1) or in the presence of 100 nM dasatinib (lane 2), HLCX (lane 3), HLCX-SS-dasatinib ADC (lane 4), or trastuzumab-SS-dasatinib (lane 5) at 37 °C, then immediately lysed. Proteins were separated on SDS-PAGE, transferred to PVDF membrane and probed with pan anti-phosphotyrosine antibody. eIF4E served as the loading control.

Scheme 1.
 Synthesis of HLCX-based antibody drug conjugates.